Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Accrued contract research and lab supplies

Accrued contract research and lab supplies at other companies

Mirion Technologies logo
Mirion TechnologiesMIR
$29.1M+6.2%
US Physical Therapy logo
US Physical TherapyUSPH
$38.97M+14.2%
United Rentals logo
United RentalsURI
$44M+7.3%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$6.81M+56.1%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$5.74M+23.5%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$218K-62.1%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.65B+259%
Enterprise value$2.64B+275%
P/S72.1×+63.7×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept nrix:AccruedContractResearchAndLabSupplies.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemMay 31,2026November 30,2025
Accrued compensation$13,449$21,541
Accrued contract research and lab supplies15,30014,952
Accrued clinical10,77413,260
Accrued professional services2,1931,944
Accrued taxes2471,059
Other1,3042,096
Total accrued expenses and other current liabilities$43,267$54,852

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s accrued contract research and lab supplies?
Nurix Therapeutics, Inc. (NRIX) reported accrued contract research and lab supplies of $15.3M in Q1 2026.
How has Nurix Therapeutics, Inc.'s accrued contract research and lab supplies changed year-over-year?
Nurix Therapeutics, Inc.'s accrued contract research and lab supplies increased by 95.3% year-over-year, from $7.83M to $15.3M.
What is the long-term trend for Nurix Therapeutics, Inc.'s accrued contract research and lab supplies?
Over 2 years (2022 to 2025), Nurix Therapeutics, Inc.'s accrued contract research and lab supplies has grown at a 52.5% compound annual growth rate (CAGR), from $6.43M to $14.95M.
What does accrued contract research and lab supplies mean?
This captures the estimated liability for research services performed by third-party contract research organizations and the cost of laboratory supplies consumed but not yet invoiced. It is a critical indicator of the company's current R&D burn rate and the pace of its clinical development pipeline.

Ask your AI about Nurix Therapeutics, Inc.'s accrued contract research and lab supplies.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude